NCT00150228 - 12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

December 31, 2001

Study Completion Date

September 30, 2002

Conditions

Smoking Cessation

Interventions

DRUG

CP-526,555 (varenicline)

Trial Locations (7)

Pfizer Investigational Site, Lexington

Pfizer Investigational Site, Albert Lea

Pfizer Investigational Site, Rochester

Pfizer Investigational Site, Philadelphia

Pfizer Investigational Site, Providence

Pfizer Investigational Site, La Crosse

Pfizer Investigational Site, Madison